Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen™ TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects

NCT02733133 is registered in ClinicalTrials.gov with Transdermal Delivery Solutions Corp as lead sponsor.

NCT NCT02733133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02733133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen™ TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects
Lead sponsor
Transdermal Delivery Solutions Corp
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 5, 2027
Completion date
December 31, 2027
Enrollment
96 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadotropism